Simulations Plus 경영진
경영진 기준 점검 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
핵심 정보
Shawn O'Connor
최고경영자
US$1.1m
총 보수
| CEO 급여 비율 | 47.85% |
| CEO 재임 기간 | 1.3yrs |
| CEO 지분 보유율 | n/a |
| 경영진 평균 재임 기간 | 1.3yrs |
| 이사회 평균 재임 기간 | 5.2yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Apr 29
SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced Future
Analysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).Seeking Alpha • Apr 12
Simulations Plus: Down Substantially, Not An Automatic Buy
Summary Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position. Despite improved margins and lower multiples, lack of growth and AI uncertainty keep me cautious on Simulations Plus. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 12
SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term Upside
Analysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).분석 기사 • Feb 08
Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some Risk
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...분석 기사 • Feb 06
Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$22.72 Simulations...
내러티브 업데이트 • Jan 07
SLP: Reaffirmed Guidance And AI Roadmap Will Support Further Upside
Analysts have trimmed their price target on Simulations Plus to about US$22.33 per share, reflecting a slightly higher discount rate and P/E assumptions that point to a more cautious stance on profitability. What's in the News Simulations Plus plans an Analyst and Investor Day focused on presenting its new product vision and AI solutions, highlighting where management is aiming future product development (Key Developments).내러티브 업데이트 • Dec 14
SLP: Reinforced Revenue Outlook Will Drive Upside From Current Levels
Analysts have modestly reduced their price target on Simulations Plus to approximately 22.33 dollars from 23 dollars. This reflects a recalibration of valuation multiples, even as they acknowledge stronger revenue growth and a significantly improved profit margin outlook.내러티브 업데이트 • Nov 29
SLP: Revenue Guidance Will Support Renewed Upside Despite Index Exclusions
Analysts have maintained their price target for Simulations Plus at $23.00. They cited stable assumptions for revenue growth, profit margins, and valuation multiples in their latest assessment.내러티브 업데이트 • Nov 15
SLP: Revenue Forecasts Will Drive Potential Gains Despite Index Removals
Analysts have modestly adjusted their price target for Simulations Plus from $23.00 to $23.00. They cite subtle changes in assumptions around discount rate and profit margins, while maintaining steady core growth expectations.내러티브 업데이트 • Nov 01
SLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed Optimism
Analysts have adjusted their price target for Simulations Plus to $23.00. This reflects slight updates in their financial forecasts and expectations for future growth and profitability.분석 기사 • Oct 28
Simulations Plus, Inc. (NASDAQ:SLP) Shares Could Be 44% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$32.42 Simulations...내러티브 업데이트 • Oct 18
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have maintained the fair value estimate for Simulations Plus at $23.00. This reflects stable long-term growth expectations, even with only slight adjustments to underlying assumptions.내러티브 업데이트 • Oct 03
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have revised their price target for Simulations Plus downward from $25.33 to $23.00, citing lower projected revenue growth and profit margins as key factors in their updated outlook. What's in the News Simulations Plus was removed from the S&P Composite 1500, S&P 1000, S&P 600, and S&P 600 Health Care indices (Key Developments).분석 기사 • Jul 31
Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% Pounding
Unfortunately for some shareholders, the Simulations Plus, Inc. ( NASDAQ:SLP ) share price has dived 25% in the last...분석 기사 • Jun 13
Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shares have had a horrible month, losing 36% after a relatively good period...분석 기사 • May 07
Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?
Key Insights The projected fair value for Simulations Plus is US$40.15 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Apr 16
Simulations Plus: Benefiting From FDA Modernization And AI
Summary Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. SLP's long-term outlook remains strong due to its innovative approach and the growing adoption of AI in drug testing, making it a "Buy" for long-term investors. Read the full article on Seeking Alpha분석 기사 • Apr 13
Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Feb 08
Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price Surge
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Jan 08
Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...분석 기사 • Nov 07
We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative
Despite posting healthy earnings, Simulations Plus, Inc.'s ( NASDAQ:SLP ) stock has been quite weak. Along with the...
새로운 내러티브 • Oct 27
Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth
Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings.Seeking Alpha • Aug 22
Simulations Plus: Declining Margins Are A Problem
Summary Simulations Plus growth is steady, but its margins continue to decline. This has been problematic due to the company's high valuation. Simulations Plus has suggested that the demand environment is improving, but its guidance implies a meaningful deceleration in organic growth. Simulations Plus likely needs to maintain its growth rate while improving margins before its share price moves higher. The decision to cut the company's dividend suggests that an improvement in margins and cash flows could be some way off. Read the full article on Seeking AlphaSeeking Alpha • Jul 10
Simulations Plus: Steady Growth, But What About The Margins?
Summary Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. Acquisition of Pro-ficiency Holdings doubles the addressable market, but uncertainty remains about growth and margins amidst a demanding valuation. Read the full article on Seeking AlphaSeeking Alpha • May 14
Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts
Summary Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and underpenetrated, providing SLP with both organic and inorganic growth opportunities. While the company is operating in an attractive market and has a strong business, the company's valuation and growth prospects make the stock unappealing. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Feb 28 2026 | n/a | n/a | -US$63m |
| Nov 30 2025 | n/a | n/a | -US$64m |
| Aug 31 2025 | US$1m | US$525k | -US$65m |
| May 31 2025 | n/a | n/a | -US$63m |
| Feb 28 2025 | n/a | n/a | US$7m |
| Nov 30 2024 | n/a | n/a | US$8m |
| Aug 31 2024 | US$2m | US$512k | US$10m |
| May 31 2024 | n/a | n/a | US$10m |
| Feb 29 2024 | n/a | n/a | US$11m |
| Nov 30 2023 | n/a | n/a | US$11m |
| Aug 31 2023 | US$2m | US$487k | US$10m |
| May 31 2023 | n/a | n/a | US$10m |
| Feb 28 2023 | n/a | n/a | US$10m |
| Nov 30 2022 | n/a | n/a | US$11m |
| Aug 31 2022 | US$1m | US$450k | US$12m |
| May 31 2022 | n/a | n/a | US$12m |
| Feb 28 2022 | n/a | n/a | US$12m |
| Nov 30 2021 | n/a | n/a | US$10m |
| Aug 31 2021 | US$1m | US$444k | US$10m |
| May 31 2021 | n/a | n/a | US$12m |
| Feb 28 2021 | n/a | n/a | US$11m |
| Nov 30 2020 | n/a | n/a | US$10m |
| Aug 31 2020 | US$739k | US$350k | US$9m |
| May 31 2020 | n/a | n/a | US$9m |
| Feb 29 2020 | n/a | n/a | US$9m |
| Nov 30 2019 | n/a | n/a | US$9m |
| Aug 31 2019 | US$425k | US$325k | US$9m |
보상 대 시장: Shawn의 총 보수(USD1.10M)는 US 시장에서 비슷한 규모 기업의 평균(USD1.74M)보다 낮습니다.
보상과 수익: Shawn의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Shawn O'Connor (65 yo)
1.3yrs
재임 기간
US$1,096,572
보수
Mr. Shawn M. O'Connor serves as Chief Executive Officer of Simulations Plus, Inc. since 2025 and had been Chief Executive Officer since June 26, 2018 until 2025. Mr. O'Connor joined Simulations Plus, Inc....
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chief Executive Officer | 1.3yrs | US$1.10m | 데이터 없음 | |
| CFO, Executive VP & Corporate Secretary | 5.4yrs | US$534.65k | 0.010% $ 29.6k | |
| Chief Operating Officer | 1yr | US$358.27k | 데이터 없음 | |
| Chief Revenue Officer | 1yr | US$488.97k | 0.44% $ 1.2m | |
| President of Services Solutions | no data | US$465.08k | 0.39% $ 1.1m | |
| Global Head of Strategic Alliances | 1yr | US$482.28k | 0% $ 0 | |
| Accounting Manager | no data | 데이터 없음 | 데이터 없음 | |
| Chief Science Officer | 5.7yrs | 데이터 없음 | 데이터 없음 | |
| VP of Corporate Counsel & Personal Data Protection Officer | no data | 데이터 없음 | 데이터 없음 | |
| Senior Director of Corporate Marketing | no data | 데이터 없음 | 데이터 없음 | |
| Vice President of Human Resources | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Science Officer of Quantitative Systems Pharmacology | 1.3yrs | 데이터 없음 | 데이터 없음 |
1.3yrs
평균 재임 기간
55yo
평균 나이
경험이 풍부한 관리: SLP의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.3 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Director | 29.9yrs | US$155.27k | 16.17% $ 46.1m | |
| Independent Chairman of the Board | 9yrs | US$193.52k | 0.082% $ 233.3k | |
| Member of Scientific Advisory Board | 5.2yrs | 데이터 없음 | 데이터 없음 | |
| Chairman of Scientific Advisory Board | 5.2yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 11.4yrs | US$180.02k | 0.072% $ 205.7k | |
| Member of Scientific Advisory Board | 5.2yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 5.2yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 5.2yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 4.4yrs | US$175.52k | 0.085% $ 242.1k |
5.2yrs
평균 재임 기간
67.5yo
평균 나이
경험이 풍부한 이사회: SLP의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.2 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 09:08 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/02/28 |
| 연간 수익 | 2025/08/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Simulations Plus, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Larsen | BTIG |
| Dane Leone | CGS International |
| Constantine Davides | Citizens JMP Securities, LLC |